A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 50
- Locations
- 2
- Primary Endpoint
- Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period
Study Overview
Brief Summary
This Phase I behavior therapy development study seeks to improve treatment outcomes for methamphetamine (MA)-dependent subjects by developing a novel cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •English-speaking adults ≥ 18 years who are seeking treatment for MA addiction.
- •Own a cellular phone with SMS text messaging capability and have an unlimited text messaging plan.
- •Available to attend CBT therapy groups.
- •Agreeable to conditions of the study and signed an informed consent form.
Exclusion Criteria
- •Projected to be unavailable > 12 hours/day to read and send text messages.
- •Any medical or psychosocial condition that would preclude safe, useful, or consistent participation,
Arms & Interventions
CBT- based SMS text messaging intervention
cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
Intervention: CBT group therapy (Behavioral)
CBT- based SMS text messaging intervention
cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
Intervention: CBT- based SMS text messaging intervention (Behavioral)
Placebo Texts
Placebo texts will be given instead of interventional texts
Intervention: CBT group therapy (Behavioral)
Outcomes
Primary Outcomes
Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period
Time Frame: 5 weeks
The primary efficacy measure for this study is the difference in proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period. Urine samples will be analyzed for MA by immunoassay with a cutoff of 1,000 ng/mL.
Secondary Outcomes
No secondary outcomes reported
Investigators
Gantt Galloway, PharmD
Senior Scientist
California Pacific Medical Center Research Institute